41 results about "Recombinant peptide" patented technology

The invention relates to isolated synthetic or recombinant peptides comprising an epitope of human tau 2N4R, wherein the tau peptide sequence comprising the epitope is not phosphorylated. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the non-phosphorylated tau epitopes and to such peptides and binding molecules, such as antibodies, for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

Use of impedance and / or dielectric spectroscopy for analysis of a eukaryotic cell expressing an endogenous or recombinant peptide or polypeptide. A sensing apparatus 30 includes a main channel 34 thro

This invention relates to the treatment of osteoarthritic pain, or pain associated with osteoarthritis, and particularly for LINK_TSG6 polypeptide for use in the treatment of osteoarthritic pain. Osteoarthritis is caused by the deterioration of cartilage in joints and is characterised by pain and a loss of mobility in the affected joints. Osteoarthritic pain results from multiple factors including bone marrow lesions, sub-articular bone attrition, synovitis, effusion and innervation of usually insensitive tissues. LINK_TSG6 is a short recombinant peptide comprising the LINK module of human TSG-6.

The present invention provides an immunogenic composition comprising recombinant peptides and proteins, the recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSV F protein peptides. The immunogenic composition comprises a secreted fusion protein comprising a soluble RSV viral antigen, which is linked to the collagen C-terminal portion by in-frame fusion to form a disulfide-linked trimeric fusion protein. The immunogenic composition can be used to generate an immune response, such as for treating or preventing RSV infection. The immunogenic composition can be used in vaccine compositions, such as as part of a preventive and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prevention, treatment and / or diagnostic methods, and related kits.

Provided herein are, inter alia, are methods for identifying a recombinant peptide with altered entropic distribution. In addition, provided herein are, inter alia, are antibody compositions that bind to integrin peptides.

The present invention provides immunogenic compositions comprising a secreted fusion protein, wherein the secreted fusion protein comprises a soluble influenza or rabies virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against influenza or rabies infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment, and / or diagnosis, and related kits.

The invention discloses a recombinant cubilose peptide and application thereof, and belongs to the technical field of recombinant peptide preparation. The amino acid sequence of the recombinant cubilose peptide is as shown in SEQ ID NO.1, and the nucleotide sequence for coding the recombinant cubilose peptide is as shown in SEQ ID NO.2. The preparation method of the recombinant cubilose peptide comprises the following steps: (1) cloning a nucleotide sequence for coding the recombinant cubilose peptide into a prokaryotic or eukaryotic expression vector to construct a recombinant expression plasmid; (2) transforming or transfecting the recombinant expression plasmid into a proper expression host cell, wherein the expression host cell is a prokaryotic cell, a eukaryotic cell or a yeast cell; (3) culturing the expression host cell, and performing induced expression or expression under proper conditions; (4) collecting an expression product, crushing or cracking, and centrifuging to obtain a supernatant or precipitate containing the recombinant cubilose peptide; and (5) purifying the recombinant cubilose peptide. The cubilose peptide is prepared by using a recombinant expression technology, the cubilose peptide has remarkable anti-aging, tightening and moisturizing effects, and a foundation is laid for industrial production of the cubilose peptide.

The present invention provides vaccine compositions, methods and uses thereof, the vaccine compositions are immunogenic compositions of secreted fusion proteins, wherein the secreted fusion proteins comprise a rabies or soluble influenza virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against rabies or influenza infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment and / or diagnosis and related kits.

The present invention provides a group of compounds for the sequestration of Adeno-associated virus (AAV) and adenovirus (AdV) neutralizing antibodies (NAbs) in a patient. The compounds comprise an inert backbone conjugated with at least one recombinant peptide comprising an epitope. The epitope is a conserved epitope that is targeted by human anti-AAV or anti-AdV NAbs. The backbone where the conserved epitope is conjugated to is a poly-lysine (PLys) or poly-acrylamide (PAA) backbone, among others. Also provided is a pharmaceutical composition comprising this type of compounds, as well as a method for use to treat an individual to inhibit the immune reaction against an AAV or AdV-based therapy. It is also possible to use synthetic compounds for an in vitro detection of anti-AAV or anti-AdV NAbs in a sample.

An immunogenic composition comprising recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSVF protein peptides. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen and a collagen C-terminal part are linked through in-frame fusion to form a disulfide bond linked trimeric fusion protein. The immunogenic compositions may be used to generate an immune response, for example, in the treatment or prevention of RSV infection. The immunogenic compositions may be used in vaccine compositions, for example as part of prophylactic and / or therapeutic vaccines. Also provided are methods of producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

Relates to the field of molecular biology, in particular to polypeptide and application thereof, and a composition for relieving or treating ultraviolet damage, oxidation, inflammation and aging and application thereof.

Disclosed are peptides that are useful as agonists of GPR56. Also disclosed are compositions comprising at least two synthetic or recombinant peptides, each of the peptides comprising a sequence selected from LLSSR, GYYCG, and NQGCKL, or a sequence that has a sequence identity of at least 60% thereto, wherein when a peptide comprises sequence a) or b) the peptide has a length of from 5-25 amino acids and wherein when a peptide comprises sequence c) the peptide has a length of from 6-26 amino acids. The compositions are useful for treating diseases or conditions such as vascular dysfunction, cardiovascular disease, impaired pancreatic -cell function, type II diabetes, impaired glucose tolerance, liver dysfunction, cirrhosis, liver cancer, depression, Alzheimer's disease, retinopathy and Attention deficit hyperactivity disorder.

The object of the invention is a recombinant protein with antibacterial properties having an amino acid sequence derived from the sequence of the M23 domain from Streptococcus thermophilus of a peptidoglycan hydrolase character, preferably in the form of a recombinant protein chimera, as well as compositions comprising it, their uses and methods utilizing thereof. The invention is based on recombinant proteins being peptidoglycan hydrolases with peptidase properties - derived from the M23 domain originating from Streptococcus thermophilus, showing a particularly high specificity to Gram (+) bacteria with a direct cross-linking bridges in peptidoglycan, and discloses the proteins of a recombinant protein chimera such as LB24, additionally comprising a bacteria cell wall binding CWT domain from Staphylococcus pettenkoferi.

The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and / or diagnostic methods, and related kits.

The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the tau epitope and to such peptides and antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

The present invention provides a recombinant peptide and an immunogenic composition comprising the recombinant peptide. The recombinant peptide comprises a soluble respiratory syncytial virus (RSV) antigen, the soluble RSV antigen comprises a recombinant F protein peptide, and the soluble RSV antigen is linked to the C-terminal part of collagen by means of in-frame fusion to form a disulfide-connected trimeric fusion protein. The immunogenic composition may be used to produce an immune response, for example, for treating or preventing an RSV infection. The immunogenic composition can be used in a vaccine composition, for example, as a part of a prophylactic and / or therapeutic vaccine.

The application discloses a kind of peptidoglycan recognition protein-D, preparation method and application, belong to biological medicine technical field.The application obtains natural peptidoglycan recognition protein-D from tussah by protein separation and purification technology, realizes the expression of peptidoglycan recognition protein-D and its derivative or analogue or partial fragment gene in host cell after resolving its primary structure (gene and protein) using genetic engineering technology, and the antibody of purified recombinant peptidoglycan recognition protein-D and its derivative or analogue or partial fragment is obtained by immunizing animal.The natural, recombinant peptidoglycan recognition protein-D and its derivative or analogue or partial fragment and its antibody of the application can be widely used for prevention, detection diagnosis, treatment and other biological medicine fields of microorganism, microorganism related molecular pattern.

More particularly, the present invention relates to immunogenic compositions comprising recombinant peptides and proteins comprising coronavirus antigens and immunogens, such as SARS-CoV-2 coronavirus Hu-1, its variant Aumitron (BA.5 and / or XBB.1. 5) variants, and / or chimeric antigens and immunogens of other variant S protein peptides or fragments thereof, variant or mutant sequences, for example, SARS-CoV-2 coronavirus Hu-1, its variant Aumitron (BA.5 and / or XBB.1. 5) variants, and / or other variant S protein peptides or fragments thereof. The immunogenic composition comprises a secretory fusion protein comprising a soluble coronavirus antigen, the soluble coronavirus antigen protein being linked by in-frame fusion to a C-terminal portion of collagen capable of self-trimerization to form a disulphide linked trimeric fusion protein. The immunogenic compositions can be used to generate immune responses, and can be used in vaccine compositions. Also provided are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

Described are methods and compositions that provide for the production and use of generating synthetic or recombinant peptides having antifungal properties. Wherein a peptide or polypeptide consists or consists essentially of an anti-fungal portion of the alpha-7 domain of EntV, wherein the peptide or polypeptide comprises an amino acid sequence.

Provided are recombinant polypeptides, pharmaceutical compositions and uses thereof, and methods of preventing or treating cancer. The recombinant polypeptide comprises a first subunit and a second subunit, the first subunit comprises all or fragments of the amino acid sequence of programmed death ligand 1 (PD-L1), and the second subunit comprises all or fragments of the amino acid sequence of a melanoma preferential expression antigen (PRAME). The dual antigen cancer vaccine co-targeting PD-L1 and PRAME effectively prevents, ameliorates or treats cancer and / or inhibits tumor growth in the prophylactic and therapeutic aspects.

The present invention relates to: a recombinant peptide in which a Mitochondria Localization Sequence (MLS) peptide and the Signal Transducer and Activator of Transcription 3 (STAT3) are fused to each other; a recombinant vector carrying a polynucleotide coding for the recombinant peptide; and a composition comprising the recombinant peptide or the recombinant vector as an active ingredient for prevention or treatment of autoimmune disease or inflammatory disease, wherein the recombinant peptide or the recombinant vector allows STAT3 to be overexpressed in the mitochondria to enhance the mitochondrial function, resulting in inhibiting the expression of inflammatory cytokines including IL-17, whereby the composition may be advantageously used for preventing or treating autoimmune disease or inflammatory diseases.

The invention belongs to the technical field of biology, and particularly relates to a preparation method and application of a Trx-sNINJ1 fusion protein and a recombinant sNINJ1 peptide. The method comprises the following steps: inserting a nucleic acid fragment containing an sNINJ1 coding gene into a pET32a vector with a Trx tag; transforming escherichia coli to express a Trx-sNINJ1 fusion protein; carrying out IPTG (isopropyl-beta-d-thiogalactoside) induced expression and purification to obtain Trx-sNINJ1 fusion protein; and removing the Trx tag through enzyme digestion to obtain the recombinant sNINJ1 peptide. The recombinant sNINJ1 peptide and the Trx-sNINJ1 fusion protein both have an immunoregulation effect, and the activity is equivalent to that of the recombinant sNINJ1 peptide. The preparation method provided by the invention is simple and rapid, low in cost and free of side reaction, and the obtained recombinant sNINJ1 peptide and the intermediate Trx-sNINJ1 fusion protein in the preparation process of the recombinant sNINJ1 peptide can be developed as drugs.

Described are recombinant immunogenic kex peptide antigens, recombinant peptide immunogens, immunogenic compositions, and methods of using such immunogens and compositions for the treatment of and protection against diseases and symptoms thereof associated with infection by or exposure to one or more fungal pathogens. Also provided are compositions and kits for detecting or quantifying the presence of antibodies directed against one or more fungal kex peptide antigens, as well as use of such antibodies to treat and protect against diseases and symptoms thereof associated with infection by or exposure to one or more fungal pathogens.

The invention belongs to the technical field of biological medicines, and provides an anti-HPV (human papillomavirus) infection recombinant III type human collagen peptide as well as a preparation method and application thereof, the amino acid sequence of the anti-HPV infection recombinant III type human collagen peptide is formed by three repetitions of a coding sequence UniProtKB: P02461 of III type human collagen from the 991st site to the 1032nd site, and is named as ATHPV3, and the amino acid sequence is shown as SEQ ID NO.1. The anti-HPV infection recombinant III type human collagen peptide can be used for preparing anti-HPV infection recombinant III type human collagen peptide. The recombinant III-type human collagen peptide with the molecular weight of about 13kD is obtained through expression and purification, the recombinant III-type human collagen peptide can be specifically combined with HPV 16 / 18 L1 protein, multiple pairs of hydrogen-bond interactions exist, and high-concentration and medium-concentration recombination can inhibit pseudovirus infection of 293T cells. The recombinant III-type human collagen peptide which is relatively good in purity, can be combined with HPV 16 / 18 L1 and can effectively inhibit HPV 16 / 18 pseudovirus infection of 293T cells is successfully obtained, and an effective candidate medicine is provided for preventing and treating HPV infection.

The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

This article provides recombinant peptides comprising engineered extracellular domains of viral proteins derived from enveloped viruses. It also provides two-component protein nanostructures and compositions for use in vaccination, generating immune responses, or treating or preventing viral infections.

The present invention relates to methods of producing a conformationally constrained peptide in cellulo using a pnictogen-containing crosslinker. The present invention also relates to conformationally constrained peptides obtainable by said methods and a method for screening peptide libraries for transcription factor agonists that tests whether said conformationally constrained peptide inhibits association between two candidate binding partners. The present invention also relates to the use of a pnictogen-containing cross-linker in a method of producing a conformationally constrained peptide in cellulo. The present invention also relates to recombinant peptides comprising three thiol- / selenol-containing residues linked to a pnictogen-containing cross-linker. The present invention also relates to a kit for use in said methods.